K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine, Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute, J Natl Cancer Inst, vol.97, issue.13, pp.966-75, 2005.

A. M. Gonzalez-angulo, B. T. Hennessy, K. Broglio, F. Meric-bernstam, M. Cristofanilli et al., Trends for inflammatory breast cancer: is survival improving?

, Oncologist, vol.12, issue.8, pp.12-20, 2007.

M. Stendahl, L. Ryden, B. Nordenskjold, P. E. Jonsson, G. Landberg et al., High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients, vol.12, pp.4614-4622, 2006.

J. Liu, H. Guo, K. Mao, K. Zhang, H. Deng et al., Impact of estrogen receptorbeta expression on breast cancer prognosis: a meta-analysis, Breast Cancer Res Treat, vol.156, issue.1, pp.149-62, 2016.

H. Ma, Y. Lu, P. A. Marchbanks, S. G. Folger, B. L. Strom et al., Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women, BCR, vol.15, issue.5, p.90, 2013.

J. Li, Y. Xia, Q. Wu, S. Zhu, C. Chen et al., Outcomes of patients with inflammatory breast cancer by hormone receptor-and HER2-defined molecular subtypes: a population-based study from the SEER program, Oncotarget, 2017.

J. Liu, K. Chen, W. Jiang, K. Mao, S. Li et al., Chemotherapy response and survival of inflammatory breast cancer by hormone receptorand HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database, J Cancer Res Clin Oncol, vol.143, issue.1, pp.161-169, 2017.

H. Masuda, T. M. Brewer, D. D. Liu, T. Iwamoto, Y. Shen et al., Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes, Ann Oncol, vol.25, issue.2, pp.384-91, 2014.

S. J. Van-laere, N. T. Ueno, P. Finetti, P. Vermeulen, A. Lucci et al., Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets, Clin Cancer Res, vol.19, issue.17, pp.4685-96, 2013.

H. D. Bear, S. Anderson, A. Brown, R. Smith, E. P. Mamounas et al., The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and bowel project protocol B-27, J Clin Oncol, vol.21, issue.22, pp.4165-74, 2003.

S. Pounds and S. W. Morris, Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values, Bioinformatics, vol.19, issue.10, pp.1236-1278, 2003.

D. Trabzuni and P. C. Thomson, Analysis of gene expression data using a linear mixed model/finite mixture model approach: application to regional differences in the human brain, Bioinformatics, vol.30, issue.11, pp.1555-61, 2014.

C. Strobl, J. Malley, and G. Tutz, An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests, Psychol Methods, vol.14, issue.4, pp.323-371, 2009.

C. B. Pereira, M. F. Leal, C. R. De-souza, R. C. Montenegro, J. A. Rey et al., Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy, PLoS One, vol.8, issue.3, p.60576, 2013.

J. Qu, X. Zhao, J. Wang, X. Liu, Y. Yan et al., MYC overexpression with its prognostic and clinicopathological significance in breast cancer, Oncotarget, vol.8, issue.55, pp.93998-4008, 2017.

A. Batistatou, V. Kotoula, M. Bobos, G. Kouvatseas, F. Zagouri et al., Correlation of MYC gene and Protein status with breast Cancer subtypes and outcome of patients treated with Anthracycline-based adjuvant chemotherapy. Pooled analysis of 2 Hellenic cooperative group phase III trials, Clinical breast cancer, vol.18, issue.1, pp.53-62, 2018.

A. R. Green, M. A. Aleskandarany, D. Agarwal, S. Elsheikh, C. C. Nolan et al., MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours, Br J Cancer, vol.114, issue.8, pp.917-945, 2016.

S. V. Fernandez, F. M. Robertson, J. Pei, L. Aburto-chumpitaz, Z. Mu et al., Inflammatory breast cancer (IBC): clues for targeted therapies, Breast Cancer Res Treat, vol.140, issue.1, pp.23-33, 2013.

J. S. Ross, S. M. Ali, K. Wang, D. Khaira, N. A. Palma et al., Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations, Breast Cancer Res Treat, vol.154, issue.1, pp.155-62, 2015.

T. Bihani, S. A. Ezell, B. Ladd, S. E. Grosskurth, A. M. Mazzola et al., Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers, Oncotarget, vol.6, issue.4, pp.2407-2420, 2015.

M. M. Heckler, H. Thakor, C. C. Schafer, and R. B. Riggins, ERK/MAPK regulates ERRgamma expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer, FEBS J, vol.281, issue.10, pp.2431-2473, 2014.

M. T. Weigel, S. Banerjee, M. Arnedos, J. Salter, A. 'hern et al., Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer, Ann Oncol, vol.24, issue.1, pp.126-159, 2013.

W. A. Woodward, Inflammatory breast cancer: unique biological and therapeutic considerations, Lancet Oncol, vol.16, issue.15, pp.146-147, 2015.

C. V. Dang, MYC on the path to cancer, Cell, vol.149, issue.1, pp.22-35, 2012.

F. Bertucci, A. Lagarde, A. Ferrari, P. Finetti, C. et al., 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer, PLoS One, vol.7, issue.5, p.37943, 2012.

C. Rypens, . Vbc, C. Billet, J. Hauspy, F. Bertucci et al., Inflammatory breast cancer cells are characterized by attenuated SMAD dependent TGF? signaling leading to impaired cell motility responses. Paper presented at the 2018 San Antonio breast Cancer symposium, 2018.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations